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Positron emission tomography (PET) plays an
importantroleintheassessmentofmyocardialbloodﬂow
(MBF). Absolute quantiﬁcation of MBF is feasible using
tracer kinetic models.
1 The most common method for
quantifying MBF involves the acquisition of dynamic
images with the cyclotron-produced radiopharmaceuti-
cals
13N-ammonia and
15O-water. An alternative method
is the use of the generator produced
82Rb.
Several cardiovascular disorders have been evalu-
ated with MBF PET. For instance, MBF measured by
PET has been undertaken in patients with coronary
artery disease (CAD), hypertrophic cardiomyopathy
(HCM), idiopathic dilated cardiomyopathy (IDCM), and
microvascular disease.
2-5
Also, important long-term prognostic value of
reduced coronary ﬂow reserve in estimated with PET
has been reported.
5-7 In other words, MBF assessment
provides a way to document and to estimate the risk of
cardiovascular events. The majority of these previous
studies are based on the MBF measurement of the entire
myocardial wall.
In this issue of the Journal of Nuclear Cardiology,
Rutten-Vermeltfoort and colleagues present interesting
data regarding the determination of subendocardial and
subepicardial MBF in 27 healthy subjects assessed with
15O-labeled water.
8 An additional MRI was performed
to measure left ventricular volumes and function. They
found that mean resting MBF in the subendocardium
was higher than the subepicardium level. Of interest,
during adenosine stress, vasodilation was augmented to
a greater extent in the subepicardium compared with the
subendocardium. The subendocardial-to-subepicardial
MBF ratio decreased signiﬁcantly during hyperemia
(1.35 ± 0.23 to 1.12 ± 0.20, P\0.001). Hyperemic
transmural MBF was inversely correlated with left
ventricular end-diastolic volume index (r
2 = 0.41,
P = 0.0003), with a greater impact at the subendocar-
dial level. The authors concluded that a transmural
perfusion gradient can be detected in normal healthy
subjects in a routine clinical setting with
15O-water PET.
Evaluation of MBF in several cardiovascular disor-
ders as mentioned previously can be optimized in a
different way by applying a split up in subendocardial and
subepicardial regions. As mentioned by the authors the
transmural perfusion gradient can be determined in
patientswithhypertrophicheartsorinpatientswithcardiac
syndrome X, for detecting microvascular dysfunction.
4,9
For several reasons this study also offers opportu-
nities for additional clinical applications, such as the
unravelling of the etiology of transient ischemic dilata-
tion (TID). An abnormal increase in TID ratio is
regarded as an important marker that may indicate
extensive CAD. It is described as an enlargement of the
left ventricle (LV) cavity during stress due to extensive
subendocardial ischemia that normalizes at rest. TID is
frequently described as a combination of true physical
dilatation of the end-diastolic volume, and apparent
dilation caused by non-visualization of the sub-endo-
cardium or by heart rate acceleration.
10
Evaluation of subendocardial infarction is another
ﬁeld of interest. The method described in this study may
assist in a better functional delineation of both layers of
the myocardial wall. Up to now, MRI has played the
leading role in the evaluation of subendothelial infarc-
tion. However, the anatomical and functional
combination of PET-CT or even PET-MRI MBF with a
contrast agent may replace the MRI approach. Absolute
quantiﬁcation of MBF is a strong tool of PET imaging,
and the better delineation of the subendocardium by
the current method in combination with CT may put
PET-CT on a higher level.
Further, one would suspect that cardiac resynchro-
nization therapy (CRT) may affect the transmural ﬂow
gradient. If so, relating the subendocardium-to-sub-
epicardium ratio to LV function may be used to evaluate
or even predict the LV response on CRT.
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544Finally, the quantiﬁcation of regional myocardial
blood ﬂow may be clinically useful not only for
assessing the extent and severity of CAD, but also to
detect and measure impairments in microcirculatory
function in non-coronary cardiac disease. The prog-
nostic signiﬁcance of transmural microcirculatory
dysfunction in the absence of CAD however remains to
be assessed.
A number of technical aspects in this study need to
be taken into account. As mentioned by the authors,
tissue surrounding the myocardium could inﬂuence
perfusion values and lead to heterogeneity of the per-
fusion pattern. Region deﬁnition of smaller areas of
interest, such as with subendocardial and subepicardial
ﬂow measurements, will introduce more noise and
potentially augment spillover artifacts from adjacent
tissue. Moreover, spillover of activity between myo-
cardial layers does occur. Simulation models and in vivo
studies have revealed that the latter will result in
underestimation of the transmural gradient.
The limited spatial resolution remains an important
drawback for accurate measurements (i.e., without bias)
of subendocardial and subepicardial MBF using PET. In
this study a PET scanner with moderate spatial resolu-
tion was used. In the last 2 decades, however, the spatial
resolution of PET scanners has signiﬁcantly improved
(from[16 to\4 mm FWHM) and the impact of patient
movement on quantiﬁcation becomes more critical as
the resolution increases. This is an area of active
development and automated robust solutions for this
long-standing issue should become available in the next
years.
It is also clear that resolution is not the only limiting
factor. Cardiac and respiratory movements pose a limi-
tation on the effective resolution achievable. Gating
(list) mode using ECG and respiratory signal was lack-
ing in this study and therefore poses a serious limitation.
This will need to be applied in the future for optimal
delineation of the subendocardial and subepicardial
layers.
Generator produced
82Rb for MBF estimation is of
more general use in imaging centers, especially in
USA. The positron range, however, of
82Rb is longer
than
13N-ammonia and
15O-water and will result in
suboptimal image resolution. Therefore, the determina-
tion of subendocardial and subepicardial MBF with
82Rb PET should be evaluated before it is applied clin-
ically. Also, PET MBF protocols will differ between
imaging centers, for instance the use of dynamic or static
images. Static images have a higher (better) signal-
to-noise ratio, but the subendocardial-to-subepicardial
MBF ratio may be reduced due to redistribution of the
tracer. On the other hand, will MBF modelling need to
be redeﬁned in dynamic imaging? Will the delineation
of different borderzones inﬂuence regional perfusion
results and should we thus redeﬁne normal perfusion and
MPR values?
Previously, the determination of subendocardial and
subepicardial MBF was validated mainly by animal
experiments and microspheres.
11 Of importance is the
reproducibility of the transmural perfusion gradient,
both test-re-test and between centers. This needs to be
addressed in future studies.
Finally, why only MBF for measurement in the
subendocardium versus the subepicardium? Of interest
may be metabolic imaging. FDG-PET, or even (neuro)
receptor imaging might beneﬁt from assessing trans-
mural gradients. Myocardial ischemia and viability may
also to be linked with metabolic
12 and neuro-receptor
gradient changes.
In summary, the data of this study are encouraging.
PET-(CT) MBF measurements may have additional
clinical value using the transmural myocardial perfusion
gradient. This ‘‘split function’’ method needs to be
further optimized before optimal clinical utility.
Open Access
This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are
credited.
References
1. Hutchins GD, Schwaiger M, Rosenspire KC, et al. Noninvasive
quantiﬁcation of regional blood ﬂow in the human heart using
N-13 ammonia and dynamic positron emission tomographic
imaging. J Am Coll Cardiol 1990;15:1032-42.
2. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J
Med 2007;356:830-40.
3. de Jong RM, Tio RA, van der Harst P, et al. Ischemic patterns
assessed by positron emission tomography predict adverse out-
come in patients with idiopathic dilated cardiomyopathy. J Nucl
Cardiol 2009;16:769-74.
4. Knaapen P, Germans T, Camici PG, et al. Determinants of coro-
nary microvascular dysfunction in symptomatic hypertrophic
cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;294:
H986-93.
5. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between
the prognostic value of left ventricular function and myocardial
perfusion reserve in patients with ischemic heart disease. J Nucl
Med 2009;50:214-9.
6. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic
value of 13 N-ammonia myocardial perfusion positron emission
tomography added value of coronary ﬂow reserve. J Am Coll
Cardiol 2009;54:150-6.
7. Slart RH, Zeebregts CJ, Hillege JL, De Sutter J, Dierckx RA, van
Veldhuisen DJ, et al. Myocardial perfusion reserve after a PET-
driven revascularization: a strong prognostic factor. J Nucl Med
(in press).
Journal of Nuclear Cardiology Slart 545
Volume 18, Number 4;544–6 Myocardial perfusion PET8. Vermeltfoort IA, Raijmakers PG, Lubberink M, Germans T, van
Rossum AC, Lammertsma AA, et al. Feasibility of subendocardial
and subepicardial myocardial perfusion measurements in healthy
normals with
15O-labeled water and positron emission tomo-
graphy. J Nucl Cardiol. doi:10.1007/s12350-011-9375-y.
9. de Vries J, DeJongste MJ, Jessurun GA, et al. Myocardial perfu-
sion quantiﬁcation in patients suspected of cardiac syndrome X
with positive and negative exercise testing: A [13 N]ammonia
positron emission tomography study. Nucl Med Commun
2006;27:791-4.
10. van der Veen BJ, Kuperij N, Stokkel MP. Transient ischemic
dilatation ratio derived from myocardial perfusion scintigraphy:
What are we looking at? J Nucl Cardiol 2010;17:207-15.
11. Rimoldi O, Schafers KP, Boellaard R, et al. Quantiﬁcation of sub-
endocardial and subepicardial blood ﬂow using
15O-labeled water
and PET: Experimental validation. J Nucl Med 2006;47:163-72.
12. Southworth R, Dearling JL, Medina RA, et al. Dissociation of
glucose tracer uptake and glucose transporter distribution in the
regionally ischaemic isolated rat heart: Application of a new
autoradiographic technique. Eur J Nucl Med Mol Imaging
2002;29:1334-41.
546 Slart Journal of Nuclear Cardiology
Myocardial perfusion PET July/August 2011